PharVision Advisers’s Smith & Wesson SWBI Stock Holding History

PharVision Advisers’s Portfolio SWBI Stock Details SWBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,248	Closed	-$176K	–	127
2026 Q1	$176K	Sell	12,248 -15,827	-56%	-$192K	1.78%	5
2025 Q4	$277K	Buy	+28,075	New	+$271K	0.14%	324

Other funds holding SWBI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

PharVision Advisers's SWBI Position: Q2 2026 in Review

PharVision Advisers sold out of Smith & Wesson (SWBI) in Q2 2026, closing a stake of 12,248 shares — an estimated $176K sold.

PharVision Advisers first reported a position in SWBI in Q4 2025 and held it in 2 quarters. The position peaked at $277K in Q4 2025. 200 funds tracked by Wall St. Rank hold SWBI as of Q2 2026.

PharVision Advisers reported no remaining Smith & Wesson position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 12,248 Smith & Wesson shares in Q2 2026, an estimated $176K.
PharVision Advisers first reported a position in Smith & Wesson in Q4 2025 and held it in 2 quarters.
PharVision Advisers's Smith & Wesson position peaked at $277K in Q4 2025.
200 funds tracked by Wall St. Rank held Smith & Wesson as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.